nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view
|
NEVEN, P. |
|
2006 |
|
s2 |
p. 505-510 |
artikel |
2 |
ANDROGENS AND BREAST CANCER
|
Franco, B. |
|
2006 |
|
s2 |
p. 493 |
artikel |
3 |
An estrogen receptor α-dependent regulation of estrogen receptor–related receptor α in the proliferation of endometrial carcinoma cells
|
SUN, P.-M. |
|
2006 |
|
s2 |
p. 564-568 |
artikel |
4 |
ANTHROPOMETRY, PHYSICAL ACTIVITY, AND ENDOMETRIAL CANCER RISK: RESULTS FROM THE NETHERLANDS COHORT STUDY
|
Schouten, L.J. |
|
2006 |
|
s2 |
p. 492 |
artikel |
5 |
An update on breast cancer prevention trials
|
WICKERHAM, D.L. |
|
2006 |
|
s2 |
p. 498-501 |
artikel |
6 |
An update on ovarian suppression/ablation
|
JAKESZ, R. |
|
2006 |
|
s2 |
p. 511-514 |
artikel |
7 |
An update on raloxifene
|
Draper, M.W. |
|
2006 |
|
s2 |
p. 502-503 |
artikel |
8 |
Association between the CHEK2*1100delC germ line mutation and estrogen receptor status
|
de BOCK , G.H. |
|
2006 |
|
s2 |
p. 552-555 |
artikel |
9 |
Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself
|
CARDOSO, F. |
|
2006 |
|
s2 |
p. 533-537 |
artikel |
10 |
Bone safety of aromatase inhibitors versus tamoxifen
|
LØNNING, P.E. |
|
2006 |
|
s2 |
p. 518-520 |
artikel |
11 |
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor–positive early breast cancer. Analysis based on the ATAC trial
|
MOEREMANS, K. |
|
2006 |
|
s2 |
p. 576-578 |
artikel |
12 |
Effects of 17β-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messengerRNA in breast cancer cells
|
MIRKIN, S. |
|
2006 |
|
s2 |
p. 560-563 |
artikel |
13 |
Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26–28, 2006
|
NEVEN, P. |
|
2006 |
|
s2 |
p. 479-491 |
artikel |
14 |
Endometrial cancer: predictors of response and preferred endocrine therapy
|
AMANT, F. |
|
2006 |
|
s2 |
p. 527-528 |
artikel |
15 |
Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients
|
MORALES, L. |
|
2006 |
|
s2 |
p. 515-517 |
artikel |
16 |
Exogenous steroids for menopausal symptoms and breast/endometrial cancer risk
|
MOURITS, M.J.E. |
|
2006 |
|
s2 |
p. 494-496 |
artikel |
17 |
Gene expression profiling of treatment resistance: hype or hope for therapeutic target identification
|
HELLEMAN, J. |
|
2006 |
|
s2 |
p. 538-542 |
artikel |
18 |
Growth patterns and the risk of breast cancer in women
|
AHLGREN, M. |
|
2006 |
|
s2 |
p. 569-575 |
artikel |
19 |
How to measure and report the estrogen (and progesterone) receptor in breast cancer
|
VERMEULEN, P.B. |
|
2006 |
|
s2 |
p. 529-532 |
artikel |
20 |
Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families
|
Jernström, H. |
|
2006 |
|
s2 |
p. 497 |
artikel |
21 |
Interleukin-1α protein secretion in breast cancer is associated with poor differentiation and estrogen receptorα negativity
|
SINGER, C.F. |
|
2006 |
|
s2 |
p. 556-559 |
artikel |
22 |
Is cancer risk related to genes for steroid receptors and estrogen metabolism?
|
LEGIUS, E. |
|
2006 |
|
s2 |
p. 549-551 |
artikel |
23 |
Is fulvestrant (“Faslodex”) just another selective estrogen receptor modulator?
|
HOWELL, A. |
|
2006 |
|
s2 |
p. 521-523 |
artikel |
24 |
Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant
|
VERGOTE, I. |
|
2006 |
|
s2 |
p. 524-526 |
artikel |
25 |
Not all selective estrogen response modulators are created equal: update on lasofoxifene
|
Goldstein, S.R. |
|
2006 |
|
s2 |
p. 504 |
artikel |
26 |
Oral Abstracts
|
|
|
2006 |
|
s2 |
p. 579-588 |
artikel |
27 |
Poster Presentations
|
|
|
2006 |
|
s2 |
p. 589-598 |
artikel |
28 |
Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists
|
JOHNSTON, S.R.D. |
|
2006 |
|
s2 |
p. 543-548 |
artikel |